Artesunate: Difference between revisions
From IDWiki
(Created page with "* Artemesinin compound indicated for the treatment of severe malaria * Dosing: ** Adults and children ≥20 kg: 2.4 mg/kg at 0 hour, 12 hours, 24 hours, and 48 hours ** Ch...") |
No edit summary |
||
| Line 1: | Line 1: | ||
== Background == |
|||
* Artemesinin compound indicated for the treatment of severe [[malaria]] |
* Artemesinin compound indicated for the treatment of severe [[malaria]] |
||
== Dosing == |
|||
| ⚫ | |||
* Adults and children ≥20 kg: 2.4 mg/kg at 0 hour, 12 hours, 24 hours, and 48 hours, followed by oral therapy |
|||
| ⚫ | |||
== Safety == |
|||
=== Post-Artesunate Delayed Hemolysis === |
|||
* Likely the result from delayed clearance of previously-infected erythrocytes rather than toxic effect of the drug |
|||
* Recommend weekly CBC for at least 4 weeks following treatment, as well as clinical monitoring for signs and symptoms of anemia and jaundice |
|||
[[Category:Antimalarials]] |
[[Category:Antimalarials]] |
||
Latest revision as of 13:53, 22 June 2021
Background
- Artemesinin compound indicated for the treatment of severe malaria
Dosing
- Adults and children ≥20 kg: 2.4 mg/kg at 0 hour, 12 hours, 24 hours, and 48 hours, followed by oral therapy
- Children <20 kg: 3.0 mg/kg at 0 hour, 12 hours, 24 hours, and 48 hours, followed by oral therapy
Safety
Post-Artesunate Delayed Hemolysis
- Likely the result from delayed clearance of previously-infected erythrocytes rather than toxic effect of the drug
- Recommend weekly CBC for at least 4 weeks following treatment, as well as clinical monitoring for signs and symptoms of anemia and jaundice
